EP1165090A2 - Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques - Google Patents

Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques

Info

Publication number
EP1165090A2
EP1165090A2 EP00916477A EP00916477A EP1165090A2 EP 1165090 A2 EP1165090 A2 EP 1165090A2 EP 00916477 A EP00916477 A EP 00916477A EP 00916477 A EP00916477 A EP 00916477A EP 1165090 A2 EP1165090 A2 EP 1165090A2
Authority
EP
European Patent Office
Prior art keywords
effective amount
pharmaceutically effective
bulimia
human
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00916477A
Other languages
German (de)
English (en)
Inventor
Gina Guadagno
Jodi M. Star
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Research Foundation
Cincinnati Childrens Hospital Research Foundation
Original Assignee
Childrens Hospital Research Foundation
Cincinnati Childrens Hospital Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Research Foundation, Cincinnati Childrens Hospital Research Foundation filed Critical Childrens Hospital Research Foundation
Publication of EP1165090A2 publication Critical patent/EP1165090A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a method of treating non-psychotic disorders by administration of antipsychotic medications. More specifically, the present invention relates to a method of treating the eating disorder Bulimia Nervosa, and bulimia-related eating disorders, by administration of antipsychotic medications from the group of compounds designated as "atypical" antipsychotic medications. In particular, this invention contemplates use of the atypical antipsychotic medication risperidone for treatment of Bulimia Nervosa and bulimia-related disorders.
  • Bulimia Nervosa (“ox like hunger of nervous origin") was identified as a mental disorder in the early 1970's, but was considered to be an "ominous" variation of the then more recognized eating disorder, anorexia nervosa. Subsequent developments in the study of eating disorders has indicated that, although many anorexia nervosa patients are, or may become bulimic, Bulimia Nervosa is a separate disorder with a distinct set of clinically-defined symptoms and behaviors.
  • the disorder anorexia nervosa can be generally characterized by an individual's refusal to maintain a minimally normal body weight usually effectuated through severe restriction of caloric intake.
  • Bulimia Nervosa and bulimia-related eating disorders are generally characterized by repeated episodes of binge eating, followed by inappropriate and unhealthy compensatory behaviors such as self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting or excessive exercise.
  • Bulimia Nervosa is of unknown etiology, but it affects a relatively large portion of the population.
  • the Diagnostic and Statistical Manual of Eating Disorders, 4 th ed., (DSM-IN) reports the prevalence of Bulimia Nervosa to be 1% to 3% within the adolescent and young adult female population, and one-tenth of that in the male population.
  • the diagnostic criteria for Bulimia Nervosa are highly defined; for a diagnosis of Bulimia Nervosa, individuals must exhibit particular behaviors and psychological symptoms with specified frequency. Frequently individuals engaging in disordered eating practices do not meet these DSM-IV criteria, but exhibit behaviors and thought patterns common to individuals diagnosed with Bulimia Nervosa, including binge eating, followed by compensatory behaviors and an undue preoccupations with body shape. These individuals are defined by the DSM-IN as having a Bulimia-Type Eating
  • Typical antipsychotic compounds function as antidopaminergic agents, primarily blocking the dopamine 2 (D2) receptors of the central nervous system, and are widely prescribed for the treatment of psychotic disorders. When used in the treatment of psychotic disorders, the compounds function to very effectively reduce "positive symptoms" of schizophrenia and related psychotic disorders, including delusions and hallucinations.
  • Typical antipsychotic compounds are well-known in the art and include drugs derived from phenothiazines, such as thioridazine and perphenazine; butyrophenone- derived compounds, such as haloperidol (Haldol); and compounds of the diphenylbutylpiperdine group, such as pimozide.
  • the precise chemical compositions and configurations of these compounds can be found in the Merck Index, 12 th ed., 1996, and are incorporated herein by reference.
  • the compounds are dopamine antagonists, binding to dopamine (D2) receptors, thereby blocking the receptors and reducing or preventing receptor-dopamine binding.
  • atypical antipsychotics to distinguish them from the “typical” or older antipsychotic medications
  • Some of the compounds, including risperidone also act as blockers of the central andrengenic receptors.
  • the current list of atypical atipsychotic drugs is well known in the art and includes, but is not limited to, clozapine (Clozaril ® ), olanzapine (Zyprexa ® ) quetiapine (Seroquel ® ) and ziprasidone.
  • the precise chemical compositions and configurations of these compounds can be found in the Merck Index, 12 th ed., 1996, and are incorporated herein by reference.
  • risperidone An additional atypical antipsychotic, also well known in the art, is risperidone, sold under the trade name "Risperdal ® " by Janssen Pharmaceuticals of Beerse, Belgium. Classified as a benzisoxazol and an atypical antipsychotic, risperidone has the properties to not only block D2 receptors, but 5HT2 receptors as well. This medication is extensively metabolized in the liver by the cytochrome P450IID6 to the principle metabolite, 9-hydroxyrisperidone. Further chemical properties and the structure of risperidone are discussed in United States Patent No.
  • risperidone 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[ 1 ,2-a]pyrimdin-4-one. Its molecular formula is C 2 H 27 FN O 2 and its molecular weight is 410.49.
  • the structural formula of risperidone is:
  • the atypical antipsychotics have been shown to reduce the occurrence of "positive” side effects in individuals suffering from psychotic disorders. They also have been shown to reduce the "negative” symptoms of 'schizophrenia, including social isolation, emotional withdrawal, decreased motivation, and subnormal communication and social skills.
  • the side effect profiles of the atypical antipsychotics are highly favorable compared to those of the typical antipsychotics.
  • clozapine reduces white blood cell counts, so its administration must be accompanied by costly blood tests to monitor for potentially fatal agranulocytosis.
  • Olanzapine has been shown to cause significant weight gain, in some cases up to 1 pound per week and is, therefore, not particularly suitable for use in a population of patients specifically fearing weight gain.
  • Quetiapine has been shown to cause cataract formation in some mammals.
  • risperidone has been shown to have few of these side effects.
  • White blood cell count remains unaffected and weight gain is minimal. The few side effects attributable to risperidone can be easily monitored and corrected.
  • the present invention achieves this objective through use of the specific atypical antipsychotic risperidone, which possesses pharmacological properties and a side effect profile particularly suitable for use in the treatment of Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S..
  • the present invention relates to the treatment of eating disorders through the use of atypical antipsychotic medications.
  • One aspect of the invention is a method of treating Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S. in a human patient by administration of a pharmaceutically effective amount of any one of the atypical antipsychotic medications known in the art.
  • the invention is directed to a method of treating Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S. in a human patient by administration of a pharmaceutically effective amount of the atypical antipsychotic medication risperidone.
  • the invention is further directed to a method of treatment of Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S. by administration of a dosage of about 0.1 to about 4.0 milligrams per day of the atypical antipsychotic medication risperidone, or of a dosage of about 1.0 to about 2.0 milligrams of risperidone per day.
  • this invention is directed to a method of treatment of Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S.
  • the dosage can be administered in any form suitable to the patient, including, but not limited to, oral, intramuscular ( ), rectal (PR) and transdermal dosage forms, or other forms known in the art.
  • the dosage form may also be selected from the group consisting of sustained release forms, controlled release forms, delayed release forms and response release forms.
  • the present invention relates to the treatment of individuals diagnosed with Bulimia Nervosa and Bulimia-Type Eating Disorder N.O.S. by the administration of any one of the atypical antipsychotic medications.
  • a patient diagnosed with either Bulimia Nervosa or Bulimia-Type Eating Disorder N.O.S. is given a pharmaceutically effective dose of any one or more atypical antipsychotic medications.
  • Any atypical antipsychotic medication, or any combinations of any such antipsychotic medications, may be utilized.
  • this method contemplates, but is not limited to, the use of the currently-known atypical antipsychotic medications: clozapine, risperidone, olanzapine, quetiapine and ziprasidone.
  • Other atypical antipsychotic medications should confer the same benefit, provided they operate upon the same physiological systems described herein.
  • the particular antipsychotic medication or medications utilized is determined by the physician on a case by case basis, through a process well known in the art which incorporates evaluation of such factors as the patient's medical history, personality, body mass and tolerance for specific side effects. Determination of a "pharmaceutically effective dosage" is also made by the treating physician who, using a method well known in the art, determines the amount which effectively treats the individual's symptoms of the eating disorder, and which either results in an absence of negative side effects or in an occurrence of such side effects at a minimal level such that the benefits experienced by the patient are not outweighed.
  • the term "pharmaceutically acceptable” as used herein is meant that the drug-active compounds and other ingredients used in the present methods are suitable for use in contact with the tissue of humans without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio.
  • Dosages may be administered orally, in liquid or pill form, or via any other suitable means known in the art including, but not limited to, intramuscular injection.
  • the duration of treatment will vary from patient to patient and will be determined by the treating physician.
  • Treatment with antipsychotic medications as described above may be combined with any other type of pharmacological or behavioral therapy known in the art for the treatment of Bulimia Nervosa or Bulimia-Type Eating Disorders N.O.S., including but not limited to antidepressant medications, anticonvulsant medications, mood stabilizer, such as lithium, cognitive behavioral therapy, individual and group psychotherapy, and relaxation techniques.
  • the atypical antipsychotic risperidone is administered to the patient in a pharmaceutically effective amount.
  • Typical dosages are from about 0.1 milligram per day to about 4 milligrams per day.
  • risperidone is administered to the patient in extremely low does, in order to minimize side effects.
  • Such dosage may consist of from about 0.1 milligram to about 1.1 milligrams of risperidone per day, or from about 0.5 to about 1.1 milligrams per day.
  • the dosage given the patient may consist from about 0.1 milligram to about 2.0 milligrams of risperidone per day.
  • the dosage can be administered in any form suitable to the patient, including, but not limited to, oral, intramuscular (IM), rectal (PR) and transdermal dosage forms, or any other forms known in the art.
  • the dosage form may also be selected from the group consisting of sustained release forms, controlled release forms, delayed release forms and response release forms. The following non-limiting example will serve to further illustrate the above- described method.
  • SM 18-year old single Caucasian female
  • SM reports an 8-month history of consuming enormous amounts of food (approximately 5,000 calories, primarily in carbohydrate form) in a discrete amount of time (less than one hour) approximately two times per day.
  • she confides that she feels a lack of control over what she is consuming.
  • she states, "I am scared to death of gaining weight [following these binges].” Therefore, she self-induces vomiting in order to avoid weight gain.
  • SM describes herself as “obese”, and “revolting to look at”, although no body characteristic in particular causes her distress. She feels like a "failure at everything" because of her perceived size. When asked to draw a picture of her body form on paper, she clearly exaggerates her body size.
  • Past Psychiatric history indicates that she was diagnosed by her Primary Care
  • SM relates that she has had remission of depressive symptoms by both Zung Depression Scores (shows depression in the mild range) and self-reported alleviation of anhedonia, insomnia, memory and concentration problems and low energy level. Her bingeing and purging has not subsided despite a therapeutic trial of an antidepressant. She has been keeping a journal of her bulimic activities on the advice of her physician for the past month. Due to her continued symptoms, SM agrees to participate in an open trial of risperidone for the treatment of Bulimia Nervosa.
  • Treatment is initiated at 0.5 mg PO twice per day of risperidone. She continues fluoxetine at her current dosage of 20 mg PO QAM. She is seen after two weeks of therapy and reassessed. Vital signs and weight are measured, and laboratory studies are conducted per protocol. She has not had any cessation of symptoms by that time. Risperidone dosage is then changed to 1.5 mg PO to be given at bedtime.
  • She is referred back to her primary care doctor for continued treatment of her disorder with risperidone and fluoxetine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un traitement de troubles non psychotiques par l'administration d'antipsychotiques atypiques, et notamment la rispéridone. D'une manière plus spécifique, l'invention concerne un traitement de la boulimie et de troubles de l'alimentation liés à la boulimie par l'administration d'antipsychotiques du groupe des composés appelés antipsychotiques atypiques. La posologie typique va de 0,1 à 4 milligrammes par jour, le médicament pouvant se présenter sous toutes les formes galéniques actuellement connues, y compris, mais pas exclusivement, orale, intramusculaire, rectale, transdermique, à libération prolongée, contrôlée, retardée ou modifiée.
EP00916477A 1999-03-18 2000-03-17 Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques Withdrawn EP1165090A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12495299P 1999-03-18 1999-03-18
US124952P 1999-03-18
PCT/US2000/007127 WO2000054764A2 (fr) 1999-03-18 2000-03-17 Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques

Publications (1)

Publication Number Publication Date
EP1165090A2 true EP1165090A2 (fr) 2002-01-02

Family

ID=22417573

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00916477A Withdrawn EP1165090A2 (fr) 1999-03-18 2000-03-17 Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques

Country Status (6)

Country Link
US (1) US6395727B1 (fr)
EP (1) EP1165090A2 (fr)
JP (1) JP2003525865A (fr)
AU (1) AU3757500A (fr)
CA (1) CA2366838A1 (fr)
WO (1) WO2000054764A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004010932A2 (fr) * 2002-07-30 2004-02-05 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
EP1575590B1 (fr) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
WO2005065660A2 (fr) * 2003-12-31 2005-07-21 Alpharma, Inc. Formulations de ziprasidone
US7744918B2 (en) 2004-11-22 2010-06-29 Hisamitsu Pharmaceutical Co., Inc. Drug-containing patch

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038152A1 (fr) 1995-06-01 1996-12-05 Eli Lilly And Company Methode de traitement de l'anorexie
GB9604465D0 (en) 1996-03-01 1996-05-01 Smithkline Beecham Plc Novel method
GB9615767D0 (en) 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment
JP2002506459A (ja) * 1997-06-27 2002-02-26 メルク シヤープ エンド ドーム リミテツド 置換された３−（ベンジルアミノ）ピペリジン誘導体およびその治療薬としての使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0054764A2 *

Also Published As

Publication number Publication date
US6395727B1 (en) 2002-05-28
WO2000054764A3 (fr) 2001-02-01
WO2000054764A2 (fr) 2000-09-21
JP2003525865A (ja) 2003-09-02
AU3757500A (en) 2000-10-04
CA2366838A1 (fr) 2000-09-21

Similar Documents

Publication Publication Date Title
Lieberman Managing anticholinergic side effects
Alexander Pharmacotherapy for post-traumatic stress disorder in combat veterans: focus on antidepressants and atypical antipsychotic agents
Hellewell Treatment-resistant schizophrenia: reviewing the options and identifying the way forward
CN115350168A (zh) 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
JP2008505923A (ja) 統合失調症患者における非定型抗精神病薬に対する補助治療としてのメマンチン
Zarate Jr et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study
McElroy et al. A 24‐week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders
AU2014281414A1 (en) Use of high dose pridopidine for treating Huntington's disease
Pakpoor et al. A review of the adverse side effects associated with antipsychotics as related to their efficacy
US6395727B1 (en) Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications
Leo et al. Atypical antipsychotic use in the treatment of psychosis in primary care
Croissant et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series
Salzman Geriatric psychopharmacology
Tariot The older patient: the ongoing challenge of efficacy and tolerability
Ketter et al. Carbamazepine and oxcarbazepine
Jalenques et al. Weight gain as a predictor of long term clozapine efficacy
RU2576611C2 (ru) Способы применения производных циклического амида для лечения шизофрении
Parellada Clinical experience and management considerations with long-acting risperidone
JP2006527238A (ja) 過剰体重又は過剰体重に対する素因を有する患者の統合失調症を治療するためのアセナピン
Currier et al. Standard therapies for acute agitation
KR20220101610A (ko) 펜플루라민을 사용하여 간질 환자를 치료하는 방법
Tablets Prescribing information
ULC Anxiolytic-Antipanic
Wedret Managing Alzheimer's disease
Pandurangi Pharmacotherapy of Psychosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011018;LT PAYMENT 20011018;LV PAYMENT 20011018;MK PAYMENT 20011018;RO PAYMENT 20011018;SI PAYMENT 20011018

R17P Request for examination filed (corrected)

Effective date: 20011018

17Q First examination report despatched

Effective date: 20021204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030415